These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Oral and Gut Microbial Dysbiosis and Non-alcoholic Fatty Liver Disease: The Central Role of Wang T; Ishikawa T; Sasaki M; Chiba T Front Med (Lausanne); 2022; 9():822190. PubMed ID: 35308549 [TBL] [Abstract][Full Text] [Related]
28. Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis. Chung KW; Cho YE; Kim SJ; Hwang S Arch Pharm Res; 2022 Apr; 45(4):229-244. PubMed ID: 35391713 [TBL] [Abstract][Full Text] [Related]
29. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697 [TBL] [Abstract][Full Text] [Related]
30. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Soejima Y; Fukusato T World J Gastroenterol; 2012 May; 18(19):2300-8. PubMed ID: 22654421 [TBL] [Abstract][Full Text] [Related]
31. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986 [TBL] [Abstract][Full Text] [Related]
32. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. Perumpail RB; Wong RJ; Ahmed A; Harrison SA Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831 [TBL] [Abstract][Full Text] [Related]
33. [Research on the natural history of non-alcoholic fatty liver disease should be taken seriously]. Zhao ZH; Liu XL; Fan JG Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):81-84. PubMed ID: 28297791 [TBL] [Abstract][Full Text] [Related]
37. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. Jayakumar S; Loomba R Aliment Pharmacol Ther; 2019 Jul; 50(2):144-158. PubMed ID: 31149745 [TBL] [Abstract][Full Text] [Related]
38. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet. Ganguly S; Muench GA; Shang L; Rosenthal SB; Rahman G; Wang R; Wang Y; Kwon HC; Diomino AM; Kisseleva T; Soorosh P; Hosseini M; Knight R; Schnabl B; Brenner DA; Dhar D Cell Mol Gastroenterol Hepatol; 2021; 12(3):891-920. PubMed ID: 34062281 [TBL] [Abstract][Full Text] [Related]
39. Obesity, fatty liver disease and intestinal microbiota. Arslan N World J Gastroenterol; 2014 Nov; 20(44):16452-63. PubMed ID: 25469013 [TBL] [Abstract][Full Text] [Related]
40. Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics. Nagashimada M; Honda M Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360773 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]